Monoclonal antibody therapy for junin virus infection

Larry Zeitlin, Joan B. Geisbert, Daniel J. Deer, Karla A. Fenton, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Do Kim, Andrew Hiatt, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, Friedrich Altmann, Clemens Gruber, Herta Steinkellner, Anna N. Honko, Ana I. Kuehne, M. Javad Aman, Sara Sahandi, Sven Enterlein & 3 others Xiaoguo Zhan, Delia Enria, Thomas Geisbert

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Countermeasures against potential biothreat agents remain important to US Homeland Security, and many of these pharmaceuticals could have dual use in the improvement of global public health. Junin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as a category A high-priority agent. There are no Food and Drug Administration (FDA) approved drugs available for preventing or treating AHF, and the current treatment option is limited to administration of immune plasma. Whereas immune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variable in quality, and poses safety risks such as transmission of transfusion-borne diseases. In an effort to develop a monoclonal antibody (mAb)-based alternative to plasma, three previously described neutralizing murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the Guinea pig model of AHF. These mAbs provided 100% protection against lethal challenge when administered 2 d after infection (dpi), and one of them (J199) was capable of providing 100% protection when treatment was initiated 6 dpi and 92% protection when initiated 7 dpi. The efficacy of J199 is superior to that previously described for all other evaluated drugs, and its high potency suggests that mAbs like J199 offer an economical alternative to immune plasma and an effective dual use (bioterrorism/public health) therapeutic.

Original languageEnglish (US)
Pages (from-to)4458-4463
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number16
DOIs
StatePublished - Apr 19 2016

Fingerprint

Junin virus
Virus Diseases
Monoclonal Antibodies
Fever
Public Health
Arenavirus
Pharmaceutical Preparations
Bioterrorism
Passive Immunization
United States Food and Drug Administration
Therapeutics
Guinea Pigs
Safety
Antibodies
Infection

Keywords

  • Hemorrhagic fever
  • Immunotherapy
  • Junin
  • Therapy

ASJC Scopus subject areas

  • General

Cite this

Monoclonal antibody therapy for junin virus infection. / Zeitlin, Larry; Geisbert, Joan B.; Deer, Daniel J.; Fenton, Karla A.; Bohorov, Ognian; Bohorova, Natasha; Goodman, Charles; Kim, Do; Hiatt, Andrew; Pauly, Michael H.; Velasco, Jesus; Whaley, Kevin J.; Altmann, Friedrich; Gruber, Clemens; Steinkellner, Herta; Honko, Anna N.; Kuehne, Ana I.; Aman, M. Javad; Sahandi, Sara; Enterlein, Sven; Zhan, Xiaoguo; Enria, Delia; Geisbert, Thomas.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 16, 19.04.2016, p. 4458-4463.

Research output: Contribution to journalArticle

Zeitlin, L, Geisbert, JB, Deer, DJ, Fenton, KA, Bohorov, O, Bohorova, N, Goodman, C, Kim, D, Hiatt, A, Pauly, MH, Velasco, J, Whaley, KJ, Altmann, F, Gruber, C, Steinkellner, H, Honko, AN, Kuehne, AI, Aman, MJ, Sahandi, S, Enterlein, S, Zhan, X, Enria, D & Geisbert, T 2016, 'Monoclonal antibody therapy for junin virus infection', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 16, pp. 4458-4463. https://doi.org/10.1073/pnas.1600996113
Zeitlin, Larry ; Geisbert, Joan B. ; Deer, Daniel J. ; Fenton, Karla A. ; Bohorov, Ognian ; Bohorova, Natasha ; Goodman, Charles ; Kim, Do ; Hiatt, Andrew ; Pauly, Michael H. ; Velasco, Jesus ; Whaley, Kevin J. ; Altmann, Friedrich ; Gruber, Clemens ; Steinkellner, Herta ; Honko, Anna N. ; Kuehne, Ana I. ; Aman, M. Javad ; Sahandi, Sara ; Enterlein, Sven ; Zhan, Xiaoguo ; Enria, Delia ; Geisbert, Thomas. / Monoclonal antibody therapy for junin virus infection. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 16. pp. 4458-4463.
@article{7fb716c94b6b48738ee3468fc76b5cce,
title = "Monoclonal antibody therapy for junin virus infection",
abstract = "Countermeasures against potential biothreat agents remain important to US Homeland Security, and many of these pharmaceuticals could have dual use in the improvement of global public health. Junin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as a category A high-priority agent. There are no Food and Drug Administration (FDA) approved drugs available for preventing or treating AHF, and the current treatment option is limited to administration of immune plasma. Whereas immune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variable in quality, and poses safety risks such as transmission of transfusion-borne diseases. In an effort to develop a monoclonal antibody (mAb)-based alternative to plasma, three previously described neutralizing murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the Guinea pig model of AHF. These mAbs provided 100{\%} protection against lethal challenge when administered 2 d after infection (dpi), and one of them (J199) was capable of providing 100{\%} protection when treatment was initiated 6 dpi and 92{\%} protection when initiated 7 dpi. The efficacy of J199 is superior to that previously described for all other evaluated drugs, and its high potency suggests that mAbs like J199 offer an economical alternative to immune plasma and an effective dual use (bioterrorism/public health) therapeutic.",
keywords = "Hemorrhagic fever, Immunotherapy, Junin, Therapy",
author = "Larry Zeitlin and Geisbert, {Joan B.} and Deer, {Daniel J.} and Fenton, {Karla A.} and Ognian Bohorov and Natasha Bohorova and Charles Goodman and Do Kim and Andrew Hiatt and Pauly, {Michael H.} and Jesus Velasco and Whaley, {Kevin J.} and Friedrich Altmann and Clemens Gruber and Herta Steinkellner and Honko, {Anna N.} and Kuehne, {Ana I.} and Aman, {M. Javad} and Sara Sahandi and Sven Enterlein and Xiaoguo Zhan and Delia Enria and Thomas Geisbert",
year = "2016",
month = "4",
day = "19",
doi = "10.1073/pnas.1600996113",
language = "English (US)",
volume = "113",
pages = "4458--4463",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Monoclonal antibody therapy for junin virus infection

AU - Zeitlin, Larry

AU - Geisbert, Joan B.

AU - Deer, Daniel J.

AU - Fenton, Karla A.

AU - Bohorov, Ognian

AU - Bohorova, Natasha

AU - Goodman, Charles

AU - Kim, Do

AU - Hiatt, Andrew

AU - Pauly, Michael H.

AU - Velasco, Jesus

AU - Whaley, Kevin J.

AU - Altmann, Friedrich

AU - Gruber, Clemens

AU - Steinkellner, Herta

AU - Honko, Anna N.

AU - Kuehne, Ana I.

AU - Aman, M. Javad

AU - Sahandi, Sara

AU - Enterlein, Sven

AU - Zhan, Xiaoguo

AU - Enria, Delia

AU - Geisbert, Thomas

PY - 2016/4/19

Y1 - 2016/4/19

N2 - Countermeasures against potential biothreat agents remain important to US Homeland Security, and many of these pharmaceuticals could have dual use in the improvement of global public health. Junin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as a category A high-priority agent. There are no Food and Drug Administration (FDA) approved drugs available for preventing or treating AHF, and the current treatment option is limited to administration of immune plasma. Whereas immune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variable in quality, and poses safety risks such as transmission of transfusion-borne diseases. In an effort to develop a monoclonal antibody (mAb)-based alternative to plasma, three previously described neutralizing murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the Guinea pig model of AHF. These mAbs provided 100% protection against lethal challenge when administered 2 d after infection (dpi), and one of them (J199) was capable of providing 100% protection when treatment was initiated 6 dpi and 92% protection when initiated 7 dpi. The efficacy of J199 is superior to that previously described for all other evaluated drugs, and its high potency suggests that mAbs like J199 offer an economical alternative to immune plasma and an effective dual use (bioterrorism/public health) therapeutic.

AB - Countermeasures against potential biothreat agents remain important to US Homeland Security, and many of these pharmaceuticals could have dual use in the improvement of global public health. Junin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as a category A high-priority agent. There are no Food and Drug Administration (FDA) approved drugs available for preventing or treating AHF, and the current treatment option is limited to administration of immune plasma. Whereas immune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variable in quality, and poses safety risks such as transmission of transfusion-borne diseases. In an effort to develop a monoclonal antibody (mAb)-based alternative to plasma, three previously described neutralizing murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the Guinea pig model of AHF. These mAbs provided 100% protection against lethal challenge when administered 2 d after infection (dpi), and one of them (J199) was capable of providing 100% protection when treatment was initiated 6 dpi and 92% protection when initiated 7 dpi. The efficacy of J199 is superior to that previously described for all other evaluated drugs, and its high potency suggests that mAbs like J199 offer an economical alternative to immune plasma and an effective dual use (bioterrorism/public health) therapeutic.

KW - Hemorrhagic fever

KW - Immunotherapy

KW - Junin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84964328690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964328690&partnerID=8YFLogxK

U2 - 10.1073/pnas.1600996113

DO - 10.1073/pnas.1600996113

M3 - Article

VL - 113

SP - 4458

EP - 4463

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -